References
- Moller P, Koretz K, Leithauser F, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithe-lium. Int J Cancer 1994; 57: 371–7.
- Leithauser F, Dhein J, Mechtersheimer G, et al. Con-stitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415–29.
- Cheng J, Zhou T, Liu C, et al. Protection from Fas-me-diated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–62.
- Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malig-nancy. Cancer Res 1996; 56: 3870–4.
- Hellquist HB. Apoptosis in epithelial hyperplastic la-ryngeal lesions. Acta Otolaryngol (Stockh) ; Suppl 1997; 527: 25–9.
- Kataoka S, Tsuruo T. Physician education: apoptosis. Oncologist 1996; 1: 399–401.
- Ashkenazi A, Pai RC, Fong S, et al. Safety and antitu-mor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–62.
- Ogawa Y, Nishioka A, Hamada N, et al. Expression of fas (CD95/APO-1) antigen induced by radiation ther-apy for diffuse B-cell lymphoma: immunohistochemical study. Clin Cancer Res 1997; 3: 2211–6.
- Muschen M, Warskulat U, Schmidt B, et al. Regula-tion of CD95 (Apo-1/Fas) ligand and receptor expres-sion in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid. Biol Chem 1998; 379: 1083–9.
- Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84: 239–43.
- Volm M, Koomagi R. The implications of proliferation and apoptosis for lung cancer metastasis. Oncol Rep 1999; 6: 373–6.
- Munker R, Younes A, Cabanillas F, Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma 1997; 27: 517–21.
- Muraki Y, Yoshioka C, Tateishi A, et al. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1999; 37: 37–40.
- Ito Y, Takeda T, Umeshita K, et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep 1998; 5: 41–4.
- Nguyen PL, Harris NL, Ritz J, Robertson MJ. Expres-sion of CD95 antigen and Bc1-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996; 148: 847–53.
- Tachibana O, Nakazawa H, Lampe J, et al. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 1995; 55: 5528–30.
- Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998; 36: 92–101.
- Shin MS, Park WS, Kim SY, et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999; 154: 1785–91.
- Yoshihiro N, Hughes SJ, et al. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998; 101: 1102–10.
- Coppola D, Schreiber RH, Mora L, et al. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999; 6: 298–304.
- Okada K, Shiku H. Expression of nm23/NDP kinase and cancer metastasis. Nippon Rinsho 1996; 54: 845–53.